Biomedical Engineering Reference
In-Depth Information
Hensley S (2001) American home products boosts its research efforts. Wall Street Journal
(May 17)
Higgins MJ, Graham SJH (2009) Balancing innovation and access: patent challenges tip the scales.
Science 326(5951):370-371. http://www.sciencemag.org/content/326/5951/370.full . Accessed
8 Aug 2011
Hill LL (2005) Patent primer: the orange book. Nature Publishing Group. 4,621
Hollis A (2005) How do brands' “own generics” affect pharmaceutical prices? Rev Ind Organ
27(4):329-350
Iizuka T (2004) What explains the use of direct-to-consumer advertising of prescription drugs?
J Ind Econ 52(3):349-379
Jain DC (2010) The sandwich strategy: managing new products amd services for value creation
and value capture. In: Tybout AM, Calder BJ (eds) Kellogg on marketing. Wiley, Hoboken, NJ,
pp 161-181
Jennewein K (2005) Intellectual property management: the role of technology-brands in appro-
priation of technological innovation. Physica-Verlag, Heidelberg
Kamien MI, Zang I (1999) Virtual patent extension by cannibalization. South Econ J
66(1):117-131
Kolassa EM (2009) The strategic pricing of pharmaceuticals. PondHouse, New York, NY
Kotler P (1988) Marketing management: analysis, planning, implementation, and control, 6th edn.
Prentice Hall, Englewood Cliffs, NJ
Labaton S (2000) Generic-drug maker agrees to settlement in price-fi xing case. The New York
Times (July 13)
Laurent L (2008) AstraZeneca gets patent heartburn relief. Forbes (April 15)
Li JS et al (2007) Economic return of clinical trials performed under the pediatric exclusivity
program. JAMA 297(5):480-488
Lichter JB, Kurth JH (1997) The impact of pharmacogenetics on the future of healthcare. Curr
Opin Biotechnol 8:692-695
Lindpaintner K (2002) The impact of phamacogenetics and pharmacogenomics on drug discovery.
Nat Rev Drug Discov 1:463-469
Lu JZ, Comanor WS (1998) Strategic pricing of new pharmaceuticals. The MIT Press
80(1):108-118
Manchanda P et al (2003) Response modeling with non-random marketing mix variables. SSRN.
http://ssrn.com/abstract=371360 . Accessed 8 Aug 2011
Mehl AB (2006) The Hatch-Waxman act and market exclusivity for generic drug manufacturers:
an entitlement of an incentive? Chicago Kent Law Rev 81(2):649-677
Mossinghoff GJ (1998) Overview of the Hatch-Waxman Act and its impact on the drug develop-
ment process. Food Drug Law J 54:187-194. http://www.regulatorypro.com/FDLI%20-%20
Overview%20of%20Hatch-Waxman%20Act%201984.pdf . Accessed 8 Aug 2011
Paige LK (1997) Premarin, politics, and the public health: an expose revealing how politics
trumped science at the FDA. Through the looking glass—a CAGW special report. http://mem
bership.cagw.org/site/PageServer?pagename=reports_premarin . Accessed 8 Aug 2011
Palczuk L et al (2004) Act two from the purple pill. http://www.allbusiness.com/marketing-
advertising/branding-brand-development/4685580-1.html . Accessed 8 Aug 2011
Parchomovsky G, Siegelman P (2002) Towards an integrated theory of intellectual property.
Virginia Law Rev 88(7):1455-1528
Rosenthal J (2002) Hatch-Waxman use or abuse—collusive settlements between brand-name and
generic drug manufacturers. Berkeley Technol Law J 17:317-335. http://heinonline.org/HOL/
Page?handle=hein.journals/berktech17&id=331&type=text&collection=journals . Accessed 8
Aug 2011
Salbu SR (1999) Off-label use, prescription, and marketing of FDA-approved drugs: an assessment
of legislative and regulatory policy. Florida Law Review 51(2):181-227
Schacht WH, Thomas JR (2002) Pharmaceutical patent term extensions: a brief explanation. CRS
Report for Congress, Penny Hill Press
Search WWH ::




Custom Search